358 related articles for article (PubMed ID: 18841277)
1. Factor IX: Insights from knock-out and genetically engineered mice.
Monahan PE
Thromb Haemost; 2008 Oct; 100(4):563-75. PubMed ID: 18841277
[TBL] [Abstract][Full Text] [Related]
2. FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis.
Kao CY; Lin CN; Yu IS; Tao MH; Wu HL; Shi GY; Yang YL; Kao JT; Lin SW
Thromb Haemost; 2010 Aug; 104(2):355-65. PubMed ID: 20539913
[TBL] [Abstract][Full Text] [Related]
3. Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice.
Wu YM; Kao CY; Huang YJ; Yu IS; Lee HS; Lai HS; Lee PH; Lin CN; Lin SW
Cell Transplant; 2010; 19(9):1169-80. PubMed ID: 20412633
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of a hemophilia B transgenic mouse model on the basis of coagulation factor IX gene knock-out mouse].
Che WL; He Y; Yao ZZ; Li J; Fu JL
Yi Chuan Xue Bao; 2002 Jul; 29(7):594-8. PubMed ID: 12143307
[TBL] [Abstract][Full Text] [Related]
5. [Non-viral gene transfer results in therapeutic factor IX levels in haemophilia B mice].
Schüttrumpf J; Milanov P; Roth S; Seifried E; Tonn T
Hamostaseologie; 2008 Oct; 28 Suppl 1():S92-5. PubMed ID: 18958345
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of hepatocyte transplantation on hemophilia B.
Tatsumi K; Ohashi K; Shima M; Nakajima Y; Okano T; Yoshioka A
Transplantation; 2008 Jul; 86(1):167-70. PubMed ID: 18622295
[TBL] [Abstract][Full Text] [Related]
7. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE
Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
[TBL] [Abstract][Full Text] [Related]
9. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
[TBL] [Abstract][Full Text] [Related]
10. Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B.
Tatsumi K; Ohashi K; Kataoka M; Tateno C; Shibata M; Naka H; Shima M; Hisanaga M; Kanehiro H; Okano T; Yoshizato K; Nakajima Y; Yoshioka A
Thromb Haemost; 2008 May; 99(5):883-91. PubMed ID: 18449417
[TBL] [Abstract][Full Text] [Related]
11. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
12. An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice.
Begbie ME; Mamdani A; Gataiance S; Eltringham-Smith LJ; Bhakta V; Hortelano G; Sheffield WP
Thromb Haemost; 2005 Dec; 94(6):1138-47. PubMed ID: 16411385
[TBL] [Abstract][Full Text] [Related]
13. Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.
Bigger BW; Siapati EK; Mistry A; Waddington SN; Nivsarkar MS; Jacobs L; Perrett R; Holder MV; Ridler C; Kemball-Cook G; Ali RR; Forbes SJ; Coutelle C; Wright N; Alison M; Thrasher AJ; Bonnet D; Themis M
Gene Ther; 2006 Jan; 13(2):117-26. PubMed ID: 16163377
[TBL] [Abstract][Full Text] [Related]
14. Engineering liver tissues under the kidney capsule site provides therapeutic effects to hemophilia B mice.
Ohashi K; Tatsumi K; Utoh R; Takagi S; Shima M; Okano T
Cell Transplant; 2010; 19(6):807-13. PubMed ID: 20573301
[TBL] [Abstract][Full Text] [Related]
15. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
16. In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Gui T; Reheman A; Funkhouser WK; Bellinger DA; Hagaman JR; Stafford DW; Monahan PE; Ni H
Thromb Res; 2007; 121(2):225-34. PubMed ID: 17490728
[TBL] [Abstract][Full Text] [Related]
17. Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability.
Metzger JM; Tadin-Strapps M; Thankappan A; Strapps WR; DiPietro M; Leander K; Zhang Z; Shin MK; Levorse J; Desai K; Xu Y; Lai K; Wu W; Chen Z; Cai TQ; Jochnowitz N; Bentley R; Hoos L; Zhou Y; Sepp-Lorenzino L; Seiffert D; Andre P
Thromb Haemost; 2015 Jun; 113(6):1300-11. PubMed ID: 25790442
[TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
Fabb SA; Dickson JG
Curr Opin Mol Ther; 2000 Oct; 2(5):601-6. PubMed ID: 11249763
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B.
Mukherjee S; Saha A; Biswas P; Mandal C; Ray K
Haemophilia; 2008 Sep; 14(5):1076-81. PubMed ID: 18540896
[TBL] [Abstract][Full Text] [Related]
20. Towards gene therapy for haemophilia B using primary human keratinocytes.
Gerrard AJ; Hudson DL; Brownlee GG; Watt FM
Nat Genet; 1993 Feb; 3(2):180-3. PubMed ID: 8499952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
